Biomea Fusion Inc宣布,其针对肥胖症治疗的BMF-650药物I期临床试验正按计划推进。该公司预计将在2026年上半年公布为期28天的减重效果数据,为投资者和医学界提供这一创新疗法的重要临床证据。
Biomea Fusion Inc宣布,其针对肥胖症治疗的BMF-650药物I期临床试验正按计划推进。该公司预计将在2026年上半年公布为期28天的减重效果数据,为投资者和医学界提供这一创新疗法的重要临床证据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.